Clinical Research Directory
Browse clinical research sites, groups, and studies.
Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer
Sponsor: Centre Oscar Lambret
Summary
The scope of the trial is to determine the preference of patients, after randomization and cross-over, for one of the two treatments. Another objective of the trial is to assess and compare the safety of each treatment.
Official title: Open Comparative Study With a Cross-over According to Patients'Preference Receiving Xeloda or UFT With Folinic Acid in Advanced or Metastatic Colo-rectal Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
89
Start Date
2005-11-14
Completion Date
2011-09
Last Updated
2026-09-17
Healthy Volunteers
No
Conditions
Interventions
XELODA
XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days. Cycle treatment duration : 21 days
TEGAFUR URACIL - FOLINIC ACID
Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days. Duration of treatment cycle : 35 days.
Locations (13)
Centre Paul Papin
Angers, France
Centre Hospitalier
Armentières, France
Centre Hospitalier de Béthune
Beuvry, France
Centre Hospitalier de CHOLET
Cholet, France
Centre Leonard de Vinci
Dechy, France
Polyclinique du Bois
Lille, France
Centre Oscar Lambret
Lille, France
Hopital Saint Vincent de Paul
Lille, France
Centre Hospitalier Regional
Lille, France
Centre Hospitalier
Roubaix, France
Centre Joliot-Curie
Saint Martin Les Boulogne, France
Centre Hospitalier
Valenciennes, France
Clinique des Dentellieres
Valenciennes, France